Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab and Atezolizumab in Advanced Non-Small Cell Lung Cancer
NCT04691817Phase 2Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in non-small cell lung cancer (NSCLC), sponsored by Abramson Cancer Center. Started Jul 2023; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04691817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691817.